Who are Tegretol®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): carbamazepine ER (Equetro), Suzetrigine (SUZ), Exparel/bupivacaine mixture, Exparel TAP + multi-modal pain regimen, Bupivacaine (Marcaine), All registered antiepileptic drugs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tegretol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tegretol® — Competitive Intelligence Brief

Tegretol® (Tegretol®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant; mood stabilizer. Area: Neurology; Psychiatry.

marketed Anticonvulsant; mood stabilizer Voltage-gated sodium channels Neurology; Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Tegretol® (Tegretol®) — University of Malaya. Tegretol (carbamazepine) stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tegretol® TARGET	Tegretol®	University of Malaya	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels
carbamazepine ER (Equetro)	carbamazepine ER (Equetro)	Massachusetts General Hospital	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels
Suzetrigine (SUZ)	Suzetrigine (SUZ)	Vertex Pharmaceuticals Incorporated	marketed	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)
Exparel/bupivacaine mixture	Exparel/bupivacaine mixture	Wake Forest University Health Sciences	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Exparel TAP + multi-modal pain regimen	Exparel TAP + multi-modal pain regimen	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Bupivacaine (Marcaine)	Bupivacaine (Marcaine)	NYU Langone Health	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant; mood stabilizer class)

Massachusetts General Hospital · 1 drug in this class
University of Malaya · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tegretol® — Competitive Intelligence Brief. https://druglandscape.com/ci/tegretol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab